Business
CTC potential as biomarker in MET inhibitor trials
CTC potential as biomarker in MET inhibitor trials.
About this update from Cellbxhealth Plc
[{"type":"text","content":"\n \n \n RNS Number : 5606M\n Angle PLC\n 12 May 2020\n \n \n \n \n \n \n \n \n \n For immediate release\n \n \n \n \n 12 May 2020\n \n \n \n \n \n \n \n \n ANGLE plc (\"the Company\")\n \n \n \n \n \n MET EXPRESSION OF PARSORTIX-HARVESTED CTCs FROM CANCER PATIENTS HAS POTENTIAL AS BIOMARKER FOR MET INHIBITOR DRUG TRIALS \n \n \n \n \n \n Potential for liquid biopsy solution to drive new areas of cancer treatment \n \n \n \n \n \n Parsortix performance demonstrates key advantages over alternative approaches\n \n \n \n \n \n \n ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company, is pleased to announce that the Liquid Biopsy Analysis Unit at the Health Research Institute of Santiago, Spain has published results of new work undertaken in head and neck cancer and non small cell lung cancer on the potential utility of a liquid biopsy-based strategy to assess MET alterations on circulating tumour cells (CTCs).\n \n \n \n \n \n MET alterations in cancer patients may provide a biomarker to evaluate which patients will benefit from treatment with a new class of drug called MET inhibitors. The MET-related cancer pathways can activate cell proliferation, survival, migration, motility, invasion, angiogenesis, apoptosis and epithelial-to-mesenchymal transition. Thus, the MET pathways have a fundamental bearing on the rate of growth and spread of cancer. \n \n \n \n \n \n MET changes have mostly been associated with metastatic patients and normally appear with progression of the cancer. Consequently the original tissue biopsy may be out-of-date and unreliable for assessing the current MET status. Repeat tissue biopsies may not be possible if the metastatic site cannot be accessed, the patient is too ill for the invasive procedure or there is insufficient tissue available for biopsy analysis. The researchers are the first to investigate the use of liquid biopsy systems to capture CTCs in order to investigate MET expression levels in the cancer, in a study comparing the utility of Parsortix to that of the leading antibody-based CTC system. \n \n \n \n \n \n The head and neck cancer results using Parsortix showed a significant association of the presence of MET positive CTCs, which was a minority of patients, and poorer overall sur...